SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
Life Science Alliance · 2023-11 · 6 (11) · e202301955
DOI: 10.26508/lsa.202301955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 10.08.2023. Verfasst von Irene López-Oreja und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEC | Spanish National Plan for Scientific and Technical Research and Innovation, EC | European Research Council, Centro de Investigación Biomédica en Red de Cáncer.
Abstract (Originalsprache)
Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms remain poorly understood. Using deep RNA-sequencing data from 298 CLL tumor samples and isogenic SF3B1 WT and K700E-mutated CLL cell lines, we characterize targets and pre-mRNA sequence features associated with the selection of cryptic 3′ splice sites upon SF3B1 mutation, including an event in the MAP3K7 gene relevant for activation of NF-κB signaling. Using the H3B-8800 splicing modulator, we show, for the first time in CLL, cytotoxic effects in vitro in primary CLL samples and in SF3B1 -mutated isogenic CLL cell lines, accompanied by major splicing changes and delayed leukemic infiltration in a CLL xenotransplant mouse model. H3B-8800 displayed preferential lethality towards SF3B1 -mutated cells and synergism with the BCL2 inhibitor venetoclax, supporting the potential use of SF3B1 inhibitors as a novel therapeutic strategy in CLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
- Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
- Hematopathology Section, Department of Pathology, Hospital Clínic, Barcelona, Spain.
- Centro de Investigación Biomédica en Red en Oncologia, Madrid, Spain.
- Universitat Pompeu Fabra, Barcelona, Spain.
- Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
ORCID-Profile: Irene López-Oreja, Heribert Playa-Albinyana, Rupal Tripathi, Manuel Irimia, Juan Valcárcel, Sophie Bonnal, Dolors Colomer
Förderung
- MEC | Spanish National Plan for Scientific and Technical Research and Innovation
- EC | European Research Council
- Centro de Investigación Biomédica en Red de Cáncer
- Centro excelencia Severo Ochoa
- Government of Catalonia | Agència de Gestió d’Ajuts Universitaris i de Recerca
- Ministerio de Economía y Competitividad
- PhD4MD Programme
- Spanish Ministry of Universities
Zitieren
APA
López-Oreja, I., Gohr, A., Playa-Albinyana, H., Giró, A., Arenas, F., Higashi, M., Tripathi, R., López-Guerra, M., Irimia, M., Aymerich, M., Valcárcel, J., Bonnal, S., & Colomer, D. (2023). SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. Life Science Alliance, 6(11), e202301955. https://doi.org/10.26508/lsa.202301955
Vancouver
López-Oreja I, Gohr A, Playa-Albinyana H, Giró A, Arenas F, Higashi M, et al. SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. Life Science Alliance. 2023;6(11):e202301955. doi:10.26508/lsa.202301955
BibTeX
@article{LpezOreja2023,
author = {López-Oreja, Irene and Gohr, André and Playa-Albinyana, Heribert and Giró, Ariadna and Arenas, Fabian and Higashi, Morihiro and Tripathi, Rupal and López-Guerra, Mònica and Irimia, Manuel and Aymerich, Marta and Valcárcel, Juan and Bonnal, Sophie and Colomer, Dolors},
title = {SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia},
journal = {Life Science Alliance},
year = {2023},
volume = {6},
number = {11},
pages = {e202301955},
doi = {10.26508/lsa.202301955}
}
EUVIMED